Detrimental Impact of Chemotherapy Dose Reduction or Discontinuation in Early Stage Triple-Negative Breast Cancer Treated With Pembrolizumab and Neoadjuvant Chemotherapy: A Multicenter Experience

Pembrolizumab combined with neoadjuvant chemotherapy (NAC) is the current standard of care in early stage triple-negative breast cancer (TNBC) based on higher event-free survival and pathological complete response (pCR) in Keynote-522 (KN-522) clinical trial. However, this aggressive five-drug regim...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical breast cancer 2024-12, Vol.24 (8), p.e701-e711.e2
Hauptverfasser:	Krishnan, Jayasree, Patel, Archit, Roy, Arya Mariam, Alharbi, Malak, Kapoor, Ankita, Yao, Song, Khoury, Thaer, Hong, Chi-Chen, Held, Nicole, Chakraborty, Anumita, Kaliniski, Pawel, Salman, Ahmed, Catalfamo, Kayla, Attwood, Kristopher, Kirtani, Vatsala, Shaikh, Saba S., Chaudhary, Lubna N., Gandhi, Shipra
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antineoplastic Agents, Immunological - administration & dosage Antineoplastic Agents, Immunological - adverse effects Antineoplastic Agents, Immunological - therapeutic use Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Chemotherapy dose reduction Chemotherapy, Adjuvant - adverse effects Chemotherapy, Adjuvant - methods Female Humans Immune related adverse events Keynote-522 regimen Middle Aged Neoadjuvant Therapy - adverse effects Neoadjuvant Therapy - methods Neoplasm Staging Pathologic complete response Retrospective Studies Triple negative breast cancer Triple Negative Breast Neoplasms - drug therapy Triple Negative Breast Neoplasms - pathology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!